[6] Ozcan, G, Singh, M, Vredenburgh, JJ. Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments. CLIN CANCER RES. 2023; 29 (1): 11-29. [7] Gion M, Remon J, Caramella C et al. Symptomatic lep...
[2] Siciliano MA, et al. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis[J] ESMO Open. 2022;7(3...
[2] Siciliano MA, et al. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis[J] ESMO Open. 2022;7(3):100465. [3] Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple...
参考文献: [1]Passaro A, Mok TSK, Attili I, Wu YL, Tsuboi M, de Marinis F, Peters S. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review. JAMA Oncol. 2023 Aug 1;9(8):1124-1131. doi: 10.1001/jamaoncol.2023.0459. PMID: 37166792. ...
[2] Hirsch, F. R. et al. Lung cancer: current therapies and new targeted treatments. Lancet 389, 299–311 (2017) [3] Sun, L. Y. et al. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lu...
1.Ruiz-Ceja KA.Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection.Biomed & Pharmacother. 2017;90:24-37. 2.https://www./Drugs/default.htm 3.A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.Clin Lung...
5.Hirsch, F.R., etal., Lung cancer: current therapies andnew targeted treatments. Lancet, 2017. 389(10066):p. 299-311. 6.Reck, M. and K.F.Rabe, Precision Diagnosis and Treatmentfor Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(9): p. 849-861. ...
[15] Angelo Delmonte, et al. Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L. 2024 ELCC, 38P. ...
[4].ASCO 2022 POSTER 9082P [5].Li J,Medha S,Zhao J,et al.Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer:A Network Meta-Analysis[J].Advances in Therapy,2018,35.
[2]H. Le, et al. Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments. 2024 WCLC. P1.12B.05. [3] H. Chen, et al. A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Che...